Three-Drug attack on rare blood cancer begins human testing
NCT ID NCT07464210
Summary
This study is testing whether adding a new oral drug called nemtabrutinib to two existing medications (bortezomib and rituximab) works better for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. The trial will enroll 19 adults in South Korea who have never received treatment for this condition. Researchers will measure how well the three-drug combination shrinks the cancer and controls its progression over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.